Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial

AIMS: In AFFIRM‐AHF, intravenous ferric carboxymaltose (FCM) reduced heart failure (HF) hospitalisations and improved quality of life versus placebo in iron‐deficient patients stabilised after an acute HF episode. This analysis explored the effects of FCM versus placebo in patients with ischaemic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Metra, Marco, Jankowska, Ewa A., Pagnesi, Matteo, Anker, Stefan D., Butler, Javed, Dorigotti, Fabio, Fabien, Vincent, Filippatos, Gerasimos, Kirwan, Bridget‐Anne, Macdougall, Iain C., Rosano, Giuseppe, Ruschitzka, Frank, Tomasoni, Daniela, van der Meer, Peter, Ponikowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Focused Issue on Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826371/
https://www.ncbi.nlm.nih.gov/pubmed/35869741
http://dx.doi.org/10.1002/ejhf.2630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826371/
https://www.ncbi.nlm.nih.gov/pubmed/35869741
http://dx.doi.org/10.1002/ejhf.2630

Ejemplares similares